The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.10
Bid: 12.90
Ask: 13.30
Change: -0.10 (-0.76%)
Spread: 0.40 (3.101%)
Open: 13.20
High: 13.20
Low: 13.05
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

Tue, 07th Sep 2021 18:16

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Victoria PLC - flooring company - Says trading continues to be solid, with consumers continuing to invest in their homes and commercial demand for flooring returning. Year-to-date, revenue is 70% ahead of the same period last year and more than 50% ahead of the same period in 2019. This is despite the extended and on-going lockdowns in Australia, that have hurt sales in that division, which makes up 15% of Victoria's revenue. The company says it continues to be involved in active negotiations on several high quality, value-creating acquisition opportunities, and has the capital in place to execute on them.

----------

Renew Holdings PLC - engineering services provider - Continues to deliver a strong trading performance in its current financial year that ends on September 30, driven by ongoing demand for its critical asset maintenance and renewals services, and continued operational progress across its diversified Engineering Services end markets. Renew now expects its full year results to be materially ahead of current market expectations with adjusted operating profit expected to be no less than GBP50 million versus a current consensus forecast of GBP45.8 million. The company says order book remains strong, underpinned by its long-term framework positions while net debt and cash generation are in line with expectations.

----------

Starwood European Real Estate Finance Ltd - investment firm - Says, despite pandemic-related disruption, the portfolio continues to perform in line with expectations. Net asset value as at June 30 stands at GBP423.7 million, down from GBP230.1 million the year before. "Given the extremely robust performance of the portfolio through even the most hostile of market tests and the ongoing uncertainty around many traditional forms of dividend income, it is our belief that the company's current share price discount to NAV represents compelling risk adjusted value," says Chair Stephen Smith.

----------

Weiss Korea Opportunity Fund Ltd - investment firm - Reports NAV per share as at June 30 of GBP2.8038, up from GBP2.4887 posted the year prior. The fund's share price at the end of June stands at GBP2.73, representing a 2.6% discount to NAV. During the six months to the end of June, the company purchases 600,000 of its own shares at a consideration of GBP1.7 million.

----------

Star Phoenix Group Ltd - investment firm - Says its current cash resources are USD1.4 million, sufficient until the end of the first quarter of 2022. Star Phoenix notes it is seeking new hydrogen projects and divestment of rig and equipment assets in Trinidad, with four offers of purchases of two production / workover rigs and other oilfield equipment have been received recently. The company notes a lease agreement for the equipment, including two fully equipped mud circulating tanks and one MCC unit have already been executed at a rental fee of USD570 per day.

----------

Voyager Life PLC - health and wellness company - Secures two new stores following the successful opening in St Andrews, Scotland. Adds that offers also have been accepted on new stores in Dundee and Edinburgh. The company notes considerable progress made over the summer, with Voyager's products now stocked in over 70 third-party retail stores in Scotland and England. "Our diversified business model, extended retail reach and growing product range has given us a platform for sustained growth," says Chief Executive Nick Tulloch.

----------

Abingdon Health PLC - developer and manufacturer of rapid tests - Reports the launch, initially for research use only, of a score-card product available alongside the AbC-19 rapid test, which provides a semi-quantitative result to indicate the strength of antibody response and possible immunity. The use of the score-card accessory alongside AbC-19TM LFD will allow scientific communities to help further understand the presence and strength of IgG neutralising antibodies following infection and/or vaccination.

----------

Poolbeg Pharma PLC - pharmaceutical company - Says the US Patent & Trademarks Office examiner reviewing the patent application around POLB 001 has indicated that the majority of the claims, including the main claim are allowable. The main claim relates to the use of p38 MAP kinase inhibitors as a class of compounds, including POLB 001, for the treatment of severe influenza through modulation of the immune response. Poolbeg anticipates receiving a formal patent grant in due course.

----------

Cap-XX Ltd - manufacturer of ultra-thin prismatic and cylindrical supercapacitors - Says Spire Healthcare Group PLC - provider of respiratory remote patient monitoring - selects the CAP-XX supercap to provide the peak power needed to deliver respiratory and pulse rate monitoring for pulmonary patients in the company's new Health Tag garment-adhered sensor.

----------

Open Orphan PLC - pharmaceutical services clinical research company - Notes Barvarian Nordic AS reporting positive results received from a human challenge study testing its respiratory syncytial virus vaccine candidate, MVA-BN RSV. hVIVO, a subsidiary of Open Orphan, conducted the phase 2 double-blinded, placebo controlled trial using its RSV human challenge study model. "We are delighted to see the positive results emerge from this RSV human challenge study with Bavarian Nordic for its RSV vaccine candidate, which was run by hVIVO. This study illustrates the Company's diverse offering across the infectious disease market," says Open Orphan Executive Chair Cathal Friel.

----------

Seed Innovations Ltd - investor with focus on medical cannabis - Notes an announcement by its portfolio company, Little Green Pharma Ltd, in which Seed holds 7.3 million shares, representing 3.1% of issued share capital. Little Green Pharma completed its first product shipment of its own branded cannabis flower medicines to the Australian market from its newly acquired Danish facility. Little Green Pharma expects to import two further flower shipments of cannabis flower medicines from its Danish facility by end October.

----------

Science Group PLC - Cambridge, England-based consulting services firm - Raises GBP18.5 million through the placing of 4.1 million new shares with existing and new institutional investors at a price of 450 pence per placing share. Net proceeds to be used to fund the company's recent purchases of shares in TP Group PLC and strengthen Science Group's balance sheet for future mergers & acquisitions.

Notes Executive Chair Martyn Ratcliffe sells 2.0 million shares at placing price. After this transaction, Ratcliffe will have an interest in 20% of the enlarged share capital of the Science Group. The company was not a party to the sale and will not receive any proceeds from the Ratcliffe's transaction.

----------

Kropz PLC - phosphate explorer and developer - Confirms that it has made its quarterly draw down requests under the equity facilities with its major shareholder ARC Fund. The company has two equity facilities, with the first being for USD40 million and the second for up to USD5 million. The sixth draw down under the first facility is for USD3 million which will be settled by the issue of 38.2 million new shares at the issue price of 6.75p per share to ARC on September 10. This is the final drawdown on this facility and it is now fully drawn. In addition, Kropz has made the third draw down request of USD400,000 under the second facility. This draw down will be settled by the issue of 7.0 million new shares at 4.20p per share to ARC, also on September 10. The proceeds drawn down from the facilities will be applied to the continuing workstreams on the Elandsfontein and Hinda projects.

----------

Maestrano Group PLC - software company - Says Network Rail has approved technology from its subsidiary Cordel for use in clearance gauging across the UK rail network. Cordel's technology will help Network Rail automate and speedup the critical task of ensuring trains safely fit through infrastructure such as platforms and tunnels. No financial details of the deal were disclosed.

----------

Kazera Global PLC - investment company - Enters into an off-take agreement for the sale of all tantalum produced by its mine in Tantalite Valley, Namibia. Kazera says three-year contract, through to the end of 2024 signed with Jiujiang Jinxin Nonferrous Metals Co Ltd, with a test sample assay already approved by the customer and airfreighted to China for factory testing.

----------

SolGold PLC - miner focused on Ecuador - Plans to rationalise its exploration portfolio to focus resources on its highest priority targets. SolGold intends to relinquish 10 of the 72 concessions held within its four 100% owned subsidiaries in Ecuador largely due to lower assessed geological prospectivity compared to its other project areas. These concessions cover 37,000 hectares in total.

----------

Metal Tiger PLC - investor in natural resources - Says its investee Sandfire Resources Ltd reported a standout intersection from 439 metres down-hole of 45 metres at 2.2% copper 1.2 kilometre south-west of the recently upgraded A4 mineral resource. Metal Tiger holds 2% uncapped net smelter royalty over circa 8,000 square kilometres of Sandfire's licence holdings in the Kalahari copper belt including PL190/2008, which hosts the A4 deposit. Metal Tiger also has a capped USD2 million 2% net smelter royalty over production from the T3 Motheo mine. Metal Tiger says drilling is continuing, with two rigs testing the true width of the mineralisation and the potential for extensions below MO-A4-207D and a third rig expected to arrive at A4 in mid-September.

----------

Pure Gold Mining Inc - Vancouver, Canada-based miner - Reports production milestones achieved at PureGold mine in Red Lake, Ontario. The company completes installation of all six CIP interstage screens and a trommel screen on the SAG mill in August, leading to a new single day record of 1,037 tonnes of ore on August 31, 30% higher than the current design capacity of 800 tonnes per day. The company says it poured 5,535 ounces of gold during the month of August, a new monthly record. "These summer months have been a turning point operationally for the PureGold Mine and we look forward to delivering on the promise of high grades, strong margins, and world-class exploration potential this year and in years to come," says President & CEO Darin Labrenz.

----------

Seraphim Space Investment Trust PLC - investment firm - Says Arqit Ltd, a quantum encryption technology firm, has completed its proposed merger with Centricus Acquisition Corp, a special purpose acquisition company. The combined company has been renamed Arqit Quantum Inc.

----------

Augmentum Fintech PLC - fintech sector-focused investor - Makes a USD10 million investment into Stockholm based consumer credit refinancing company AnyFin. "Their focus on improving the financial well-being of consumers through innovative digital products is a mission that resonated strongly with us. We look forward to working with them as they achieve their vision over the coming years which includes a wider product offering and growth across Europe," says Augmentum Fintech CEO Tim Levene.

----------

Albion Venture Capital Trust PLC - investment firm - Reports net asset value as at June 30 of GBP73.4 million or 73.81p per share, an increase of 0.9% since March 31. After accounting for the first dividend for the year to the end of March 2022 of 1.83p per share and the special dividend of 15.00p per share paid on July 30, the NAV is 56.98p per share. During the period from April 1 to June 30, the company did not buy back any shares.

----------

Marwyn Value Investors Ltd - investment firm - Expects to secure a cash payment after Praesepe PLC - to which it sold Le Chameau Group PLC in 2012 - won the dispute with HMRC on the principle of fiscal neutrality. The basis of the dispute was that some similar forms of gambling were treated differently for VAT purposes. On June 30, the first-tier tribunal ruled in favour of Praesepe PLC and HMRC confirmed that it will not appeal that decision. In addition, Marwyn Value Investors says it plans to distribute cash to investors received from the Praesepe VAT reclaims and investee Zegona Communications PLC in relation to proposed GBP335 million return to investors after sale of Euskaltel.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.